Search
Surrozen Inc
SRZNAdd to Watchlist
33.680USD
+17.520+108.42%
Close 09-24 16:00（ET）
391.02MMarket Cap
LossP/E TTM
After-hours 17:00 (ET)34.000USD+0.220+0.65%
After-hours 17:00 (ET)About Surrozen Inc Company
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Surrozen Inc Profile
Ticker SymbolSRZN
Company nameSurrozen Inc
IPO dateNov 23, 2020
CEOParker (Craig C)
Number of employees40
Security typeOrdinary Share
Fiscal year-endNov 23
Address171 Oyster Point Blvd
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504752820
Websitehttps://www.surrozen.com
Ticker SymbolSRZN
IPO dateNov 23, 2020
CEOParker (Craig C)
Company Executives of Surrozen Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
2.34K
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
2.34K
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
2.34K
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
2.34K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Dr. Yang Li, Ph.D.
Dr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
19.58K
+8.51%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
18.24K
+9.14%
FAQs
Who are the top five shareholders of Surrozen Inc?
The top five shareholders of Surrozen Inc are: Dr. Yang Li, Ph.D.
How many institutions hold shares of Surrozen Inc (SRZN)?
As of 2026Q1, 78 institutions hold shares of Surrozen Inc, with a combined market value of approximately 10.96M, accounting for 94.38% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2007039.00.